Insulet Corporation $PODD Shares Acquired by Candriam S.C.A.

Key Points

• Candriam S.C.A. significantly increased its stake in Insulet Corporation by 152.4%, acquiring an additional 32,120 shares, bringing its total ownership to approximately 53,192 shares valued at $13.97 million.
• Several hedge funds, including Banco Bilbao Vizcaya Argentaria and BI Asset Management Fondsmaeglerselskab A S, also boosted their holdings in Insulet during the first quarter, indicating a strong interest from institutional investors.
• Insulet reported a 32.9% revenue increase year-over-year and earnings per share of $1.17, surpassing analyst expectations, which positions the company favorably against a backdrop of analyst upgrades and a consensus "Moderate Buy" rating.

Candriam S.C.A. boosted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 152.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 53,192 shares of the medical instruments supplier's stock after buying an additional 32,120 shares during the period. Candriam S.C.A. owned approximately 0.08% of Insulet worth $13,969,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Larson Financial Group LLC increased its stake in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT purchased a new stake in Insulet during the first quarter worth about $26,000. SouthState Corp increased its stake in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Insulet during the fourth quarter worth about $42,000. Finally, Ramirez Asset Management Inc. purchased a new stake in Insulet during the first quarter worth about $53,000.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PODD shares. Canaccord Genuity Group boosted their price target on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays boosted their price target on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Stock Up 0.9%

PODD traded up $2.92 on Friday, reaching $330.77. The company's stock had a trading volume of 499,504 shares, compared to its average volume of 705,185. The stock has a 50 day moving average of $300.94 and a two-hundred day moving average of $285.91. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $23.28 billion, a price-to-earnings ratio of 100.54, a P/E/G ratio of 2.77 and a beta of 1.35. Insulet Corporation has a fifty-two week low of $180.31 and a fifty-two week high of $334.18.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.